New combo therapy shows promise for rare, aggressive skin cancer
NCT ID NCT03921008
First seen Jan 10, 2026 · Last updated May 24, 2026 · Updated 19 times
Summary
This study tests a treatment plan for people with a rare and aggressive skin cancer called cutaneous angiosarcoma. Participants first receive a chemotherapy drug (paclitaxel) alone, then the same drug combined with radiation therapy, followed by surgery to remove the cancer. The goal is to see if this approach can stop the cancer from coming back and improve survival. The trial enrolls 20 adults with localized disease that can be measured.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS ANGIOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.